Clinical Trial Update: Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating inhaled tobramycin delivered by the eFlow Rapid Nebulizer in cystic fibrosis patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: Novartis | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED